Copyright
©2013 Baishideng Publishing Group Co.
World J Respirol. Nov 28, 2013; 3(3): 77-103
Published online Nov 28, 2013. doi: 10.5320/wjr.v3.i3.77
Published online Nov 28, 2013. doi: 10.5320/wjr.v3.i3.77
Cell type | LPAR1 | LPAR2 | LPAR3 | LPAR4 | LPAR5 | LPAR6 | Ref. |
NHBEs | +++ | ++ | +++ | - | + | + | [41] |
NHBEs | +++ | ++ | +++ | - | ++ | + | [59] |
NHBEs | ++ | ++ | ++ | - | NA | NA | [43] |
HBE | ++ | ++ | NA | NA | NA | NA | [56] |
HBE (BEAS-2B) | ++ | ++ | ++ | + | ++ | + | [59] |
HBE (HBEpCs) | +++ | + | ++ | + | + | NA | [209] |
HBE (HBEpCs) | ++ | ++ | ++ | NA | NA | NA | [46] |
HBE (HBEpCs) | ++ | ++ | ++ | NA | NA | NA | [49] |
HBE (HBEpCs) | ++ | ++ | ++ | NA | NA | NA | [68] |
Primary mouse tracheal EpCs | ++ | +++ | ++ | ++ | - | NA | [57] |
NHBE cells | ++ | ++ | ++ | - | NA | NA | [43] |
A549 alveolar epithelial carcinoma | ++ | NA | NA | NA | NA | NA | [40] |
A549 alveolar epithelial carcinoma | +++ | + | - | - | NA | NA | [74] |
NCI-H522 lung epithelial carcinoma | - | ++ | + | - | NA | NA | [74] |
RLCNR rat lung adenocarcinoma | NA | NA | - | NA | ++ | NA | [283] |
Primary mouse lung fibroblasts | +++ | + | + | + | ++ | NA | [31] |
human fetal lung fibroblasts MRC5 | +++ | ++ | ++ | + | + | NA | [226] |
Mouse embryonic fibroblasts | +++ | ++ | + | +++ | + | NA | [101] |
NHLFs CCL-151 | +++ | + | ++ | + | + | ++ | [81] |
NHLFs | ++ | ++ | NA | NA | NA | NA | [42] |
Primary mouse lung endothelial | ++ | + | - | +++ | + | NA | [31] |
HPAECs | + | ++ | + | + | + | +++ | [106] |
HMVECs | + | ++ | + | + | + | +++ | [106] |
HEV ECs | NA | NA | NA | ++ | NA | ++ | [116] |
Human eosinophils | + | - | + | NA | NA | NA | [148] |
Primary mouse neutrophils | - | +++ | - | - | + | NA | [31] |
Primary mouse alveolar macrophages | - | + | + | + | + | NA | [31] |
Human alveolar macrophages | + | ++ | ++ | NA | NA | NA | [158] |
Rat alveolar macrophages | ++ | + | - | NA | NA | NA | [158] |
Human monocytes | + | - | - | NA | NA | NA | [176] |
Mouse DCs | ++ | ++ | ++ | NA | NA | NA | [58] |
Human immature DCs | + | + | + | NA | NA | NA | [172] |
Human mature DCs | + | + | + | NA | NA | NA | [172] |
Human immature DCs | - | + | - | NA | NA | NA | [174] |
Human mature DCs | - | + | - | NA | NA | NA | [174] |
Mouse immature DCs | ++ | + | +++ | ++ | +++ | NA | [175] |
Mouse mature DCs | +++ | + | + | ++ | ++ | NA | [175] |
Jurkat T cells | + | +++ | - | NA | NA | NA | [178] |
Jurkat T cells | + | + | + | NA | NA | NA | [295] |
Human CD4 T cells | + | +++ | NA | NA | NA | NA | [177] |
Human CD4 T cells | + | +++ | - | NA | NA | NA | [176] |
Human CD8 T cells | - | - | - | NA | NA | NA | [176] |
Mouse CD4 T cells | + | + | + | + | + | NA | [31] |
Mouse CD8 T cells | + | +++ | + | + | ++ | NA | [31] |
Human B lymphocytes | - | + | + | NA | NA | NA | [176] |
Human platelets | + | NA | + | NA | NA | NA | [296] |
Human platelets | + | + | + | NA | NA | NA | [295] |
Human platelets | + | + | + | + | + | NA | [297] |
Human mast cells | + | + | + | + | NA | NA | [199] |
Human mast cells | + | + | + | - | NA | NA | [200] |
Human mast cells | - | ++ | + | - | +++ | ++ | [201] |
Lung resident mesenchymal stem cells | +++ | + | + | NA | NA | NA | [298] |
Cell type | Primary | Species | LPA effect | Receptor | Experiment | Carrier | Ref |
Alveolar and bronchial epithelial | Yes | Mouse | Apoptosis | LPAR1 | In vivo | Biological fluid | [41] |
Alveolar and bronchial epithelial | Yes | Mouse | Apoptosis | LPAR2 | In vivo | Biological fluid | [41,42] |
NHBEs | Yes | Human | (anchorage dependent) Apoptosis | LPAR1 | In vitro | FAF BSA | [41] |
NHBEs | Yes | Human | TSLP, CCL20 induction | In vitro | No | [50] | |
NHBEs | Yes | Human | TGF-β activation | LPAR2 | In vitro | No | [43] |
NHBEs | Yes | Human | Induction of Soluble ST2 expression | LPAR1,3 | In vitro | NA | [61] |
Bronchial epithelial (HBEpCs) | Yes | Human | EGFR transactivation, IL-8 secretion | In vitro | BSA; BSA | [46,49] | |
Bronchial epithelial (HBEpCs) | Yes | Human | Induction of IL-13 Ralpha 2 | Gαi linked | In vitro | No | [54] |
Bronchial epithelial (HBEpCs) | Yes | Human | Epithelial barrier integrity enhancement | LPAR1,3 | In vitro | NA; BSA | [56,209] |
Bronchial epithelial (HBEpCs) | Yes | Human | Decrease of EGFR-EGF binding | In vitro | BSA | [66] | |
Bronchial epithelial (HBEpCs) | Yes | Human | COX-2 expression, PGE2 secretion | Gαi linked | In vitro | No | [63] |
Bronchial epithelial (HBEpCs) | Yes | Human | PDGFR-β transactivation | In vitro | BSA | [68] | |
Bronchial epithelial (HBEpCs) | Yes | Human | c-Met redistribution on the membrane | In vitro | No | [70,299] | |
Bronchial epithelial (BEAS-2B) | No | Human | EGFR transactivation | In vitro | BSA | [66] | |
Bronchial epithelial (BEAS-2B) | No | Human | RANTES inhibition | LPAR1 | In vitro | FAF BSA | [59] |
R3/1 Alveolar epithelial | No | Rat | Inhibition of attachment | In vitro | FAF BSA | [41] | |
Tracheal epithelial | Yes | Mouse | COX-2 expression, PGE2 secretion | LPAR2 | In vitro/vivo | No | [57] |
H292 lung cancer epithelial | No | Human | Decrease of EGFR-EGF binding | In vitro | BSA | [66] | |
A549 alveolar epithelial carcinoma | No | Human | Decrease of EGFR-EGF binding | In vitro | BSA | [66] | |
A549 alveolar epithelial carcinoma | No | Human | p53 decrease | In vitro | FAF BSA | [73] | |
A549 alveolar epithelial carcinoma | No | Human | Cell migration | LPAR1 | In vitro | BSA; BSA | [40,74] |
NCI-H522 lung epithelial carcinoma | No | Human | Cell motility | In vitro | BSA | [74] | |
Fetal lung fibroblasts (HFL1) | No | Human | Chemotaxis | In vitro | Biological fluid | [31] | |
NLFs CCL151 | No | Human | Proliferation, EGFR ectodomain shedding | Gi/o linked | In vitro | No | [81] |
Fetal lung fibroblasts MRC5 | No | Human | proliferation | LPAR1,3 | In vitro | No | [226] |
Fetal lung fibroblasts IMR-90 | No | Human | Chemotaxis | LPAR1 | In vitro | [95] | |
NLFs | Yes | Human | Differentiation, TGF-β expression and signaling | LPAR2 | In vitro | No | [42] |
Lung fibroblasts | Yes | Mouse | Differentiation, TGF-β expression and signaling | LPAR2 | In vitro | No | [42] |
Lung fibroblasts | Yes | Mouse | Chemotaxis | LPAR1 | In vitro | FAF BSA | [31] |
Lung fibroblasts | Yes | Mouse | Protection from apoptosis | LPAR1 | In vitro | FAF BSA | [41] |
NIH 3T3 fibroblasts | No | Mouse | Protection from apoptosis, proliferation | Gi linked | In vitro | FAF BSA | [99] |
NIH 3T3 fibroblasts | No | Mouse | Migration, protection from apoptosis, proliferation | In vitro | BSA | [100] | |
Rat1/c-Myc fibroblasts | No | Rat | Protection from apoptosis | In vitro | FAF BSA | [99] | |
Lung endothelial | Yes | Mouse | Vascular leak/extravasation | LPAR1 | In vivo | Biological fluid | [31] |
HPAECs pulmonary endothelial | Yes | Human | Increase of the endothelial layer permeability | LPAR6 | In vitro | FAF BSA | [106] |
BPAE pulmonary artery endothelial | No | Bovine | Migration, chemotaxis | In vitro | FAF BSA | [127-129] | |
Smooth muscle cells | Yes | Rabbit, cat | Contraction | Ex vivo | BSA | [140] | |
HASM airway smooth muscle cells | Yes | Human | Proliferation, stimulation of EGFR signaling | In vitro | NA; BSA | [139,141] | |
HASM airway smooth muscle cells | Yes | Human | Activation of TGF-β | In vitro | NA | [143] | |
Dendritic cells | Yes | Mouse | Inhibition of activation | LPAR2 | In vitro, in vivo | FAF BSA | [58] |
Lung resident mesenchymal stem cells | Yes | Human | Migration | LPAR1 | In vitro | No | [298] |
- Citation: Magkrioti C, Aidinis V. Autotaxin and lysophosphatidic acid signalling in lung pathophysiology. World J Respirol 2013; 3(3): 77-103
- URL: https://www.wjgnet.com/2218-6255/full/v3/i3/77.htm
- DOI: https://dx.doi.org/10.5320/wjr.v3.i3.77